Tenaya Therapeutics, Inc.
TNYAHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Tenaya Therapeutics, Inc. (TNYA) is listed under Biotechnology. With a market capitalization of $87.2M, it sits in micro-cap territory. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Market Cap
$87.2M
Beta
2.88
P/E (TTM)
—
P/E (Fwd)
-0.99
EPS (TTM)
$-0.52
EPS (Fwd)
$-0.39
ROE
-121.9%
ROA
-47.9%
Cash
$78.1M
Total Debt
$3.9M
Free CF
-$32.6M
52W Change
-76.6%
Annual Financials
Cash vs Debt
Where TNYA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TNYA finished 47.22% below its 150-day moving average ($0.72) and 47.95% below its 200-day moving average ($0.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TNYA overbought or oversold?
At the October 20, 2026 close, TNYA's RSI(14) was 20.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $78.1M in cash and $3.9M in debt, TNYA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$32.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -121.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, TNYA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TNYA.